Loading
Cancer Cells and Metastasis / Immune Cells in Cancer · Journal article
Cancer Research · September 8, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review that challenges the established paradigm of cancer-associated fibroblasts as the principal drivers of tumor ECM remodeling, proposing instead that non-fibroblast stromal cells play underappreciated roles in shaping the tumor microenvironment. The source outlines a conceptual framework linking ECM dynamics to invasiveness, immune evasion, and therapy resistance, but provides no new empirical evidence or quantitative synthesis to support the proposed model.
Journal article. Tumor microenvironment; non-fibroblast stromal cells in cancer.
Aberrant ECM remodeling in tumors is characterized by altered deposition, enzymatic cross-linking, degradation, and organization of matrix molecules that contribute to tumor invasiveness, immune evasion, and resistance to therapy Non-fibroblast cell populations engage in dynamic crosstalk and collectively shape the biochemical and biomechanical landscape of tumors, a role currently underappreciated relative to cancer-associated fibroblasts Therapeutic strategies targeting non-fibroblast stromal players could disrupt pro-tumor ECM dynamics, enhance anti-tumor immunity, and restore tissue homeostasis
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review proposes a reframing of stromal cell contributions to tumor biology that may inform future therapeutic development; however, it does not provide evidence strong enough to change current clinical practice and should be read as a conceptual call for broader research attention to understudied cell populations.
A narrative review article proposing a conceptual framework that challenges the fibroblast-centric model of ECM remodeling; raises questions about non-fibroblast stromal contributions rather than testing or confirming a specific empirical claim.
This review proposes a reframing of stromal cell contributions to tumor biology that may inform future therapeutic development; however, it does not provide evidence strong enough to change current clinical practice and should be read as a conceptual call for broader research attention to understudied cell populations.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Aberrant extracellular matrix (ECM) remodeling in tumors is characterized by altered deposition, enzymatic cross-linking, degradation, and organization of matrix molecules that in turn can contribute directly to tumor invasiveness, immune evasion, and resistance to therapy. Traditionally, cancer-associated fibroblasts (CAFs) have been considered the principal architects of ECM remodeling in tumors. However, the role of non-fibroblast cell populations in modulating ECM structure and function and how these processes intersect with immune regulation, metabolism, and metastasis is also crucial but currently underappreciated. Challenging the prevailing fibroblast-centric paradigm, this review provides an overview of how non-fibroblast cell types engage in dynamic crosstalk and collectively shape the biochemical and biomechanical landscape of tumors. Therapeutic strategies targeting these alternative stromal players could disrupt pro-tumor ECM dynamics, enhance anti-tumor immunity, and restore tissue homeostasis. Thus, a comprehensive understanding of the intricate network of non-fibroblast stromal cells within the tumor microenvironment (TME) can help elucidate opportunities for precision medicine and personalized cancer care, leading to the development of innovative therapeutic interventions targeting the TME.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.